Posted by Varun Renjen, M.D. on June 24th, 2021.
On June 7, 2021, the FDA approved Biogen’s Aduhelm® (aducanumab) for Alzheimer’s disease. As the first potentially disease-modifying therapy for Alzheimer’s, it could have some significant impacts on the market for Alzheimer’s therapies.
Varun Renjen, M.D., outlines those potential impacts in this short video.